Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Heather Franklin
AddedMar 31, 2024
UpdatedMay 31, 2026
Heather Franklin

Heather Franklin

Board Member, XOMA Royalty

CrunchbaseLinkedIn

Heather Franklin's Career

XOMA Royalty
XOMA Royalty

Emeryville, CA, US

Board Member· Board
Blaze Bioscience
Blaze Bioscience

Seattle, WA, US

Co-Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Heather Franklin's Career

XOMA Royalty
XOMA Royalty
Public$295.8M961981Emeryville, CA, US
Board Member· Board

Recent news

The startup behind open source tool Polars raises $21M from AccelTechCrunch · 2025

Leadership at XOMA Royalty

Owen HughesOwen HughesBoard Member
W. Denman Van NessW. Denman Van NessBoard Member
Jack L. WyszomierskiJack L. WyszomierskiBoard Member
Joe LimberJoe LimberBoard Member

Similar to XOMA Royalty

Royalty PharmaRoyalty PharmaNew York City, NY, USBiopharma, Royaltiesest. 1996Royalty PharmaNew York City, NY, US · est. 1996

NYC-based Royalty Pharma plc acquires and co-funds biopharmaceutical innovations for future royalties.

Public75
OmerosOmerosSeattle, WA, USTherapeuticsest. 1994OmerosSeattle, WA, US · est. 1994

Seattle-based Omeros develops and commercializes therapeutics for inflammation, coagulopathies, and CNS disorders.

Public · $972M196
Moma TherapeuticsMoma TherapeuticsCambridge, MA, USPrecision Medicinesest. 2020Moma TherapeuticsCambridge, MA, US · est. 2020

MOMA Therapeutics, a biotech firm, is dedicated to discovering precision medicines by unlocking molecular complexities.

Series B · $236M75
BiotechonomyBiotechonomyNewton, MA, USBiotechonomyNewton, MA, US

Biotechonomy: A venture capital firm specializing in equity financing and management aid for innovative life science startups.

6
Blaze Bioscience
Blaze Bioscience
Series B$55.4M382010Seattle, WA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Blaze Bioscience

Jim OlsonJim OlsonCo-Founder
Jan OhrstromJan OhrstromBoard Member
Dr James Olson \"Jim\"Dr James Olson \"Jim\"Board Member

Heather Franklin's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Heather Franklin

Justin LyonsJustin LyonsFounder · Blaze GlobalChristopher ViolasChristopher ViolasFounder · BlazeCarol BruckCarol BruckCo-Founder & CEO · Blizuujohn daviesjohn daviesCEO · Blaze Public RelationsColin GoddardColin GoddardBoard Member · Human Genome SciencesTyler CardonTyler CardonCEO · TheBlaze